Xin Lang Cai Jing·2025-12-09 13:41Core Viewpoint - The stock price of Tailong Pharmaceutical (600222) experienced significant volatility after the announcement of a potential change in ownership, initially rising to the limit but then plummeting to a drop limit, ultimately closing down 4.43% on the day of resumption of trading [1][4]. Group 1: Ownership Change - Tailong Pharmaceutical's controlling shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd. (Tairong Investment), is planning to transfer shares, which may lead to a change in control of the company [3][6]. - Tairong Investment intends to transfer 50.1 million shares to Jiang Pharmaceutical Group Jiangxi Medical Holdings Co., Ltd. (Jiang Pharmaceutical Holdings) at a price of 11.043 CNY per share, representing a premium of over 28% compared to the pre-suspension price of 8.58 CNY per share [3][6]. - Following the completion of the transaction, the controlling shareholder will change from Tairong Investment to Jiang Pharmaceutical Holdings, and the actual controller will shift from the Zhengzhou High-tech Industrial Development Zone Management Committee to the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [3][6]. Group 2: Financial Performance - During Tairong Investment's tenure, Tailong Pharmaceutical's performance has been inconsistent, with a revenue increase of 22.2% in 2022, the highest growth since 2018, but a net profit loss [7]. - In the first three quarters of 2024, Tailong Pharmaceutical's revenue declined to 1.187 billion CNY, a year-on-year decrease of 11.47%, and the net profit attributable to shareholders was 25 million CNY, down 12.36% year-on-year [4][7].